Proprietary cell lines offer opportunities for achieving high AAV titers.
Buffers, stabilizers, and cryoprotectants play major roles in cell therapy formulations.
Developing freeze-drying processes requires patience and deep product and process understanding.
Product and process understanding are essential to effective resin selection.
A look at how linker technology for antibody drug conjugates has evolved.
Preparing for variability and flexible processing are necessary for success.
There is no such thing as a perfect linker.
Using a systematic approach and achieving run-to-run consistency are essential.
Process and bioreactor performance are directly impacted by real-time monitoring capabilities.
Stable producer cell lines show real promise despite continued development challenges.